Meeting
2021 ASCO Annual Meeting
A randomized phase II trial of adjuvant pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153.
Authors
Greg Andrew Durm
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
Greg Andrew Durm , Muhammad Furqan , Lawrence Eric Feldman , Malini Patel , Richard Delmar Hall , Shadia Ibrahim Jalal , Thomas J. Birdas , Kenneth Kesler , Karen Marie Rieger , DuyKhanh Ceppa , Nasser H. Hanna
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT04317534
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS8583)
DOI
10.1200/JCO.2021.39.15_suppl.TPS8583
Abstract #
TPS8583
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
Alliance A031501: Phase III randomized adjuvant study of MK-3475 (pembrolizumab) in muscle-invasive and locally advanced urothelial carcinoma (MIBC) (AMBASSADOR) versus observation.
First Author: Andrea B. Apolo
Poster
2017 ASCO Annual Meeting
A phase II study of atezolizumab as neoadjuvant and adjuvant therapy in patients (pts) with resectable non-small cell lung cancer (NSCLC).
First Author: Dwight Hall Owen
Poster
2016 ASCO Annual Meeting
EORTC-ETOP randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab versus placebo for patients with early stage non small cell lung cancer (NSCLC) after resection and standard adjuvant chemotherapy: PEARLS (NCT02504372).
First Author: Mary E.R. O'Brien
Poster
2023 ASCO Annual Meeting
IMPORT-201 (IMP-MEL): A phase 1 first-in-human dose finding/randomized phase 2 study of a novel iNKT agonist IMM60 and pembrolizumab for advanced melanoma and metastatic non-small cell lung cancer (NSCLC).
First Author: Nicholas Coupe